By using the chimeric antibody to treat PCM, we found that after treatment, the group treated with αDEC/P10 had almost basal production of IFN-γ and IL-10, and all groups produced large amounts of IL-4. The gene discussed is IL10; the disease is paracoccidioidomycosis.